Compare Quest Diagnostics Inc (DGX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Verizon Communications Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Verizon Communications Inc trades at $42.96 (market cap $177.34B). The key difference: Verizon Communications Inc is far larger — about 7.8× Quest Diagnostics Inc's market cap, and Verizon Communications Inc pays the higher dividend (6.66%). Which is the better fit depends on your goals.
| DGX | VZ | |
|---|---|---|
Market Cap | $22.80B | $177.34B |
Sector | Health | Media |
52-Week High | $216.02 | $51.38 |
52-Week Low | $166.42 | $38.40 |
Enterprise Value | $28.82B | $364.84B |
Dividend Yield | 1.67% | 6.66% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Verizon (VZ) trades at $42.68, up 1.33% today, with a bearish technical signal from moving averages but recent earnings beats. The stock offers a 6.7% dividend yield with a consensus price target of $47.57, indicating 11.5% upside. Revenue grew to $138.19B in 2025, with a net income margin of 12.46%, while debt levels remain elevated at $144B total debt. Recent news highlights competitive threats from SpaceX's Starlink but also new partnerships like the 5G deal with BMW.
Outlook: VZ presents a value opportunity with a low P/E of 10.4 and strong cash flow, but faces significant competitive and debt-related risks. The stock is suitable for income-focused investors seeking defensive yield, though growth is constrained by industry saturation and rising capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
